Regencell Bioscience Holdings Limited (RGC) Comparison with companies in other sectors?

Regencell Bioscience Holdings Limited has a share price of 494.49M. You can analyze Regencell Bioscience Holdings Limited (RGC) competitors across different market sectors through stock heatmaps.

What are RGC's NET and operating margins?

Regencell Bioscience Holdings Limited (RGC) operating margin is around 0.00, and net profit margin is approximately 0.00 as of the latest reports.

In what way does RGC's earnings per share (EPS) trend reflect its financial momentum?

Regencell Bioscience Holdings Limited (RGC) EPS is -0.01 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Regencell Bioscience Holdings Limited is -1505.00, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Regencell Bioscience Holdings Limited?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Regencell Bioscience Holdings Limited like P/E which is -48.11, P/B which is 23.94, and PEG which is -0.48. Compare them with sector averages to evaluate if the stock is priced fairly.

Regencell Bioscience Holdings Limited

RGC•NASDAQ

Healthcare

Drug Manufacturers - Specialty & Generic

$15.05

$-0.13(-0.86%)

Fundamental Analysis of Regencell Bioscience Holdings Limited (RGC)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$-0.01

P/E Ratio

-1505.00

ROE

-0.50%

Net Margin

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$7.44B

Shares OutstandingTotal number of shares issued

$494.49M

Book Value/ShareNet worth per share

$0.63

Revenue/ShareAnnual revenue per share

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-0.01

Net MarginNet income as percentage of revenue

Operating MarginOperating income as percentage of revenue

ROEReturn on shareholders' equity

-49.76%

ROAReturn on total assets

-48.47%

ROCEReturn on capital employed

-53.42%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

Cash/ShareCash and equivalents per share

$0.61

FCF YieldFree cash flow as percentage of market cap

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for RGCFinancial Ratios Analysis details for RGC are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for RGCSector Benchmarking details for RGC are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Regencell Bioscience Holdings Limited Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Regencell Bioscience Holdings Limited. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Regencell Bioscience Holdings Limited's unique business strengths and challenges.

Key Financial Metrics for Regencell Bioscience Holdings Limited

For Regencell Bioscience Holdings Limited, essential financial indicators include EPS -0.01, PE -1505.00, and ROE -0.50. These key ratios reveal insights into Regencell Bioscience Holdings Limited's profitability, valuation, and operational health. Understanding these metrics enables you to compare Regencell Bioscience Holdings Limited with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Regencell Bioscience Holdings Limited

Metrics like Net Margin - and ROA -48.47% shed light on how well Regencell Bioscience Holdings Limited is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Regencell Bioscience Holdings Limited can sustain its operations and continue growing in the future.

Valuation and Market Position of Regencell Bioscience Holdings Limited

Using ratios such as P/B Ratio 23.94 and PEG Ratio -0.48, investors can assess whether Regencell Bioscience Holdings Limited is appropriately valued based on its financials and growth potential. These figures, combined with Regencell Bioscience Holdings Limited's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Regencell Bioscience Holdings Limited

Financial health indicators, such as Debt/Equity Ratio 0.01 and Cash Flow -, provide a snapshot of Regencell Bioscience Holdings Limited's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Regencell Bioscience Holdings Limited, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Regencell Bioscience Holdings Limited

Investing in Regencell Bioscience Holdings Limited based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Regencell Bioscience Holdings Limited focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;